Kyverna Therapeutics Announces Publication of Registrational Miv-cel Data in Patients with Stiff Person Syndrome in JAMA Neurology

Kyverna’s miv-cel shows strong mobility gains in SPS, but detailed efficacy data remain limited.

What the company is saying

Kyverna Therapeutics is emphasizing the publication of its KYSA-8 registrational trial results for miv-cel (KYV-101) in stiff person syndrome (SPS) in JAMA Neurology, framing the data as transformative for a disease with no approved therapies. The company highlights statistically significant improvements at 16 weeks post-treatment, with all patients discontinuing chronic immunotherapies and 67% of those previously needing walking aids regaining independent mobility. The narrative stresses a well-tolerated safety profile, with no high-grade CRS, ICANS, or IEC-HS observed. CEO Warner Biddle and lead investigator Dr. Marinos Dalakas are quoted to reinforce the potential of miv-cel to reverse disability and redefine SPS treatment. The announcement also references three FDA RMAT designations for miv-cel and ongoing trials in other autoimmune diseases, positioning Kyverna as a leader in neuroimmunology. The tone is confident and forward-looking, focusing on unmet need and urgency to bring miv-cel to patients.

What the data suggests

The KYSA-8 trial enrolled 26 adult SPS patients with inadequate response to at least one immunotherapy, each receiving a single dose of miv-cel. At 16 weeks, all patients discontinued chronic immunotherapies, and among 12 patients who required walking aids at baseline, 67% no longer needed assistance. The safety profile was described as consistent and well-tolerated, with no high-grade CRS, ICANS, or IEC-HS, but no granular adverse event rates or efficacy statistics were disclosed. SPS is a rare disease affecting an estimated 6,000 people in the United States, with up to 80% losing mobility. More than 100 patients have been treated with miv-cel across autoimmune diseases, but only headline clinical outcomes are provided. The absence of detailed endpoint data, p-values, or long-term follow-up limits independent assessment of the therapy’s true impact. The data support miv-cel’s potential but do not fully substantiate claims of reversing disability or transforming care.

Analysis

The announcement presents positive clinical trial results for miv-cel in stiff person syndrome, highlighting statistically significant improvements and a favorable safety profile in a Phase 2 trial. The narrative is optimistic, emphasizing the potential for miv-cel to transform treatment and patient outcomes, but most of these claims are forward-looking and aspirational, such as 'potential to liberate patients' and 'potential to redefine treatment.' While the trial results are promising, the data disclosed is limited to high-level outcomes (e.g., 67% of patients no longer needing walking assistance) without detailed efficacy or safety statistics. No financial, commercial, or regulatory submission timelines are provided, and there is no discussion of revenue, expenses, or profitability. The absence of granular data and commercial milestones means the announcement cannot be rated above weak_positive, and the tone is moderately inflated relative to the evidence.

Risk flags

• ●The trial was single-arm and enrolled only 26 patients, limiting the generalizability and statistical power of the findings. Without a control group, placebo effect or regression to the mean cannot be excluded.
• ●No detailed efficacy or safety data (such as p-values, adverse event rates, or long-term durability outcomes) are disclosed, making it difficult to independently verify the magnitude and durability of benefit or risk.
• ●The absence of FDA-approved therapies for SPS means regulatory approval for miv-cel would be a first, introducing uncertainty around regulatory requirements and commercial uptake.
• ●The company’s claims of transformative impact and potential to reverse disability are not fully substantiated by the disclosed data, raising the risk of overpromising relative to actual clinical benefit.
• ●No financial, manufacturing, or commercialization details are provided, so the cost, scalability, and market readiness of miv-cel remain unknown.

Bottom line

Kyverna’s publication of the KYSA-8 trial results for miv-cel in SPS demonstrates promising short-term clinical outcomes, with 67% of previously mobility-impaired patients regaining independence and all patients discontinuing chronic immunotherapies at 16 weeks. The safety profile appears favorable, but the lack of granular efficacy and safety data prevents a full assessment of risk and benefit. While the company positions miv-cel as a potential paradigm shift for SPS and other autoimmune diseases, the evidence provided is preliminary and based on a small, uncontrolled trial. Regulatory approval and commercial impact are not imminent, as timelines and next steps are not specified. Investors should recognize the strong unmet need and early clinical promise, but also the considerable execution, regulatory, and data-maturity risks. The most important takeaway is that miv-cel shows real potential in SPS, but further detailed data and regulatory clarity are needed before its market impact can be credibly assessed.

Announcement summary

(NASDAQ:KYTX) Kyverna Therapeutics, Inc. announced the publication of the primary analysis of KYSA-8, its registrational trial of miv-cel (mivocabtagene autoleucel, KYV-101) in patients with stiff person syndrome (SPS), in the Journal of the American Medical Association (JAMA) Neurology. The KYSA-8 data were also presented at the American Academy of Neurology (AAN) Annual Meeting in April 2026 and one-year durability data were shared at MS Toronto, the joint ACTRIMS-ECTRIMS meeting. Marinos C. Dalakas, MD, PhD, Professor of Neurology at Thomas Jefferson University, served as senior author and lead study investigator. In the KYSA-8 trial, a single dose of miv-cel delivered statistically significant improvements across all primary and secondary endpoints at 16 weeks, with all patients discontinuing chronic immunotherapies. Of the 12 patients who required walking aid assistance at baseline, 67% no longer needed walking assistance at 16 weeks. The safety profile of miv-cel was consistent and well-tolerated, with no high-grade CRS or ICANS, and no cases of IEC-HS. The KYSA-8 trial was a single-arm registrational Phase 2 trial enrolling 26 adult patients with SPS who had an inadequate response to at least one immunotherapy treatment, each receiving a single dose of miv-cel. The primary endpoints were change from baseline in the Timed 25-Foot Walk (T25FW) at 16 weeks and the incidence and severity of adverse events. Secondary endpoints included the Modified Rankin Scale (mRS), Distribution-of-stiffness Index (DSI), Heightened Sensitivity Scale (HSS), and Hauser Ambulation Index (HAI). Miv-cel is a fully human, autologous, CD19-targeting CAR T-cell therapy with CD28 co-stimulation, designed for potency and tolerability, and is under investigation for B-cell driven autoimmune diseases. To date, more than 100 patients have been treated with miv-cel across a range of autoimmune diseases. SPS is a rare, progressive neurologic autoimmune disease that causes up to 80% of patients to lose mobility, requiring walking aid assistance or wheelchair use. An estimated 6,000 patients are diagnosed with SPS in the United States. There are currently no FDA-approved treatments for SPS. Kyverna’s lead candidate, miv-cel, has received three FDA Regenerative Medicine Advanced Therapy (RMAT) designations in SPS, generalized myasthenia gravis (gMG), and non-active secondary progressive multiple sclerosis (naSPMS). Kyverna is also conducting an ongoing registrational trial for gMG.

Disagree with this article?